Description
What happens when a drug people can buy in everyday stores behaves like an opioid—yet regulators still treat it as a “gray zone”?
In The Lancet Pulse episode, host Matthew Gilbert and co-host Niall Boyce are joined by Dr. Liza Hutchison, Assistant Professor of Family Medicine at the University of Michigan, an addiction medicine physician overseeing services at a federally qualified health center in Washtenaw County, Michigan, and supervising a statewide telehealth on-demand buprenorphine service. Dr. Hutchison explains how natural leaf kratom contains multiple alkaloids (serotonergic, noradrenergic, and opioid-acting), with only about 1% opioid-active component, while concentrated 7-hydroxymitragynine (7-OH) products are reported to be 15–20 times more potent and can drive rapid tolerance, opioid-like withdrawal, and overdose risk.
They also discuss the clinical use of buprenorphine/Suboxone (reducing overdose death risk by 50%+ in traditional opioid use disorder), policy proposals in Michigan (including a prohibition bill), and why naloxone reverses the opioid-like breathing suppression but not other causes like seizure or liver injury.
The Lancet Pulse is part of the Lancet Group podcast offering.
Editorial team: Chloe Wilson, Ben Abbott, Matthew Gilbert, and Jonathan Pimm
Podcast editing and production: Matteo Simonetti
Visit https://www.thelancet.com/multimedia (https://www.thelancet.com/multimedia?dgcid=buzzsprout_podcast_tlp_mm) to learn more about our multimedia offering.
Find the best science for better lives at https://www.thelancet.com
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet (https://linkedin.com/company/the-lancet)
https://youtube.com/thelancettv (https://www.youtube.com/thelancettv)